UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~ 16February 10, 2025

T2 BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36571

20-4827488

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

101 Hartwell Avenue, Lexington, Massachusetts 02421

(Address of principal executive offices, including Zip Code)

(781) 761-4646

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading Symbol~~TradingSymbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		TTOO		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1 3.01. ~~Entry~~Notice ~~into~~of Delisting or Failure to Satisfy a ~~Material~~Continued ~~Definitive~~Listing ~~Agreement~~Rule or Standard.

On ~~January~~February 1610, 2025, T2the ~~Biosystems,~~Nasdaq ~~Inc.~~Stock ~~(the~~Market LLC (“~~Company~~Nasdaq”) ~~entered~~notified ~~into~~T2 ~~Amendment~~Biosystems, NoInc. 12 ~~to Term Loan Agreement~~ (the “~~Twelfth Amendment~~Company”), ~~with~~that ~~CRG~~the ~~Servicing~~Nasdaq ~~LLC~~Hearings asPanel ~~administrative agent and collateral agent~~ (inthe ~~such capacities,~~ “~~Administrative Agent~~Panel”) ~~and~~has ~~the~~determined ~~lenders~~to ~~listed~~delist on the ~~signature~~Company’s ~~pages~~common ~~thereto~~stock toand ~~modify~~that ~~certain~~trading ~~terms~~ of ~~that~~the ~~certain~~Company’s ~~Term~~common ~~Loan~~stock ~~Agreement,~~will ~~dated~~be assuspended ofat ~~December 30,~~the ~~2016,~~open byof ~~and~~trading ~~among~~on ~~the Company~~February 12, ~~the Administrative Agent and the lenders party thereto~~2025.

~~The~~As ~~Twelfth~~previously ~~Amendment~~reported, ~~waives~~the ~~certain~~Company ~~events~~was ofin ~~default~~violation ~~under~~of the ~~Term~~bid ~~Loan~~price ~~Agreement;~~requirement ~~permits~~of ~~interest~~Nasdaq ~~payable~~Listing ~~under~~Rule 5550(a)(2) (the ~~loans~~“Bid toPrice beRule”) ~~paid~~and ~~entirely~~the market value of listed securities requirement in~~-kind~~ onListing Rule 5550(b)(2) (the ~~maturity~~“MVLS ~~date;~~Rule”). ~~increases~~In accordance with the ~~final~~terms ~~payment~~of ~~fee~~the ~~from~~previously ~~10%~~imposed to“Mandatory ~~14%;~~Panel ~~extends~~Monitor” ~~the~~as ~~interest-only~~that ~~payment~~term ~~period~~is ~~from~~defined ~~December 31,~~in ~~2025~~Nasdaq toListing ~~March 31~~Rule 5815(d)(4)(B), ~~2026;~~the ~~and~~Nasdaq ~~extends~~Listing Qualifications Staff (the ~~maturity~~“Staff”) ~~date~~issued ~~from~~a ~~December 31~~delist determination, ~~2025~~which tohad ~~March 31,~~previously ~~2026~~been stayed as a result of the Company requesting a hearing.

The ~~foregoing~~Company ~~summary~~does isnot ~~qualified~~intend into ~~its~~pursue ~~entirety~~any byfurther ~~reference~~appeal toof the ~~Twelfth~~delisting ~~Amendment,~~determination. aThe ~~copy~~Company ofexpects ~~which~~that Nasdaq will befile ~~attached~~a asForm 25-NSE with anthe ~~exhibit~~Securities toand Exchange Commission (the “SEC”), which will remove the Company’s ~~Quarterly~~common ~~Report~~stock ~~on Form 10-K for the~~from ~~period~~listing ~~ending~~and ~~December 31,~~registration ~~2024~~on Nasdaq.

In the interim, the Company’s common stock is expected to begin trading under its current trading symbol (“TTOO”) on the OTC Markets system effective with the open of the markets on February 12, 2025. The Company plans to submit an application to the OTCQX for quotation of its common stock, and plans to continue to file its required periodic reports and other filings with the SEC. The Company can provide no assurance that its common stock will continue to trade on this market, whether broker-dealers will continue to provide public quotes of its common stock on this market, or whether the trading volume of its common stock will be sufficient to provide for an efficient trading market for existing and potential holders of its common stock.

Cautionary Statement Concerning Forward-Looking Statements

Statements in this Current Report that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the delisting of the Company’s common stock from Nasdaq and trading in the common stock on the OTC Market system or the OTCQX Market, and the impact on the Company’s business operations. Forward-looking statements are based on the Company’s current expectations and assumptions, which may not prove to be accurate. These statements are not guarantees and are subject to risks, uncertainties, and changes in circumstances that are difficult to predict, and significant contingencies, many of which are beyond the Company’s control, that could cause actual results to differ materially and adversely from any of these forward-looking statements. The Company cautions that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to: potential risks associated with trading on the OTC Market system or the OTCQX Market, including liquidity constraints and limited regulatory oversight; and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, as updated by any subsequent Quarterly Reports on Form 10-Q filed with the SEC, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking statements represent management’s estimates as of the date of this Current Report on Form 8-K. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 17, 2025

T2 BIOSYSTEMS, INC.

Date: February 11, 2025

T2 BIOSYSTEMS, INC.

/s/ John Sprague

John Sprague

Chief Financial Officer

Filing Compare · T2 Biosystems, Inc.